Impel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	20.99	12.65	0.67	0	0
Revenue Growth (YoY)	155.29%	1794.01%	-	-	-
Cost of Revenue	9.95	6.5	0.69	0	0
Gross Profit	11.03	6.16	-0.02	0	0
Selling, General & Admin	76.99	77.89	50.9	17.04	12.75
Research & Development	4.16	11.46	20.56	28.3	28.81
Other Operating Expenses	1.48	0	0	0	0
Operating Expenses	82.63	89.34	71.46	45.33	41.57
Operating Income	-71.59	-83.18	-71.49	-45.33	-41.57
Interest Expense / Income	12.38	13.84	4.24	0	-0.42
Other Expense / Income	-9.69	9.29	0.81	0.46	0.68
Pretax Income	-74.28	-106.31	-76.53	-45.8	-41.83
Income Tax	0	0	0	0	0.03
Net Income	-74.28	-106.31	-76.54	-45.8	-41.86
Preferred Dividends	0	0	0.13	0.52	0.51
Net Income Common	-74.28	-106.31	-76.67	-46.32	-42.36
Shares Outstanding (Basic)	24	23	15	1	0
Shares Outstanding (Diluted)	24	23	15	1	0
Shares Change	0.17%	60.58%	2770.31%	46.57%	-
EPS (Basic)	-3.12	-4.53	-5.25	-91.05	-122.07
EPS (Diluted)	-3.12	-4.53	-5.25	-91.05	-122.07
Free Cash Flow	-81.98	-95.02	-66.77	-40.97	-38.01
Free Cash Flow Per Share	-3.45	-4.05	-4.57	-80.53	-109.53
Gross Margin	52.58%	48.66%	-3.44%	-	-
Operating Margin	-341.13%	-657.48%	-10701.50%	-	-
Profit Margin	-353.93%	-840.28%	-11476.80%	-	-
Free Cash Flow Margin	-390.60%	-751.02%	-9995.81%	-	-
EBITDA	-59.42	-90.3	-71.2	-44.72	-41.52
EBITDA Margin	-283.14%	-713.69%	-10659.13%	-	-
Depreciation & Amortization	2.48	2.18	1.09	1.08	0.72
EBIT	-61.9	-92.48	-72.29	-45.8	-42.25
EBIT Margin	-294.96%	-730.93%	-10822.01%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).